170 related articles for article (PubMed ID: 38554489)
21. Boosting Anti-tumour Immunity Using Adjuvant Apigenin.
Huang J; Chen X; Chang Z; Xiao C; Najafi M
Anticancer Agents Med Chem; 2023; 23(3):266-277. PubMed ID: 35616683
[TBL] [Abstract][Full Text] [Related]
22. Targeting the innate immune system with nanoparticles for cancer immunotherapy.
Li K; Zhang Z; Mei Y; Li M; Yang Q; Wu Q; Yang H; He L; Liu S
J Mater Chem B; 2022 Mar; 10(11):1709-1733. PubMed ID: 35179545
[TBL] [Abstract][Full Text] [Related]
23. Immune microenvironment of gliomas.
Gieryng A; Pszczolkowska D; Walentynowicz KA; Rajan WD; Kaminska B
Lab Invest; 2017 May; 97(5):498-518. PubMed ID: 28287634
[TBL] [Abstract][Full Text] [Related]
24. Breaking Tumor Immunosuppressive Network by Regulating Multiple Nodes with Triadic Drug Delivery Nanoparticles.
Yan W; Li Y; Zou Y; Zhu R; Wu T; Sun X; Yuan W; Lang T; Yin Q; Li Y
ACS Nano; 2023 Sep; 17(18):17826-17844. PubMed ID: 37690028
[TBL] [Abstract][Full Text] [Related]
25. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment.
Yang M; Li J; Gu P; Fan X
Bioact Mater; 2021 Jul; 6(7):1973-1987. PubMed ID: 33426371
[TBL] [Abstract][Full Text] [Related]
26. Natural Killer Cell Interactions With Myeloid Derived Suppressor Cells in the Tumor Microenvironment and Implications for Cancer Immunotherapy.
Zalfa C; Paust S
Front Immunol; 2021; 12():633205. PubMed ID: 34025641
[TBL] [Abstract][Full Text] [Related]
27. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
28. Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma.
Minnema-Luiting J; Vroman H; Aerts J; Cornelissen R
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29601534
[TBL] [Abstract][Full Text] [Related]
29. The Role of Different Immunocompetent Cell Populations in the Pathogenesis of Head and Neck Cancer-Regulatory Mechanisms of Pro- and Anti-Cancer Activity and Their Impact on Immunotherapy.
Starska-Kowarska K
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980527
[TBL] [Abstract][Full Text] [Related]
30. Nanomaterials targeting tumor associated macrophages for cancer immunotherapy.
Zhao C; Pang X; Yang Z; Wang S; Deng H; Chen X
J Control Release; 2022 Jan; 341():272-284. PubMed ID: 34813877
[TBL] [Abstract][Full Text] [Related]
31. Novel Therapeutic Strategies for Solid Tumor Based on Body's Intrinsic Antitumor Immune System.
Duan H
Cell Physiol Biochem; 2018; 47(2):441-457. PubMed ID: 29794415
[TBL] [Abstract][Full Text] [Related]
32. Modulation of the tumor microenvironment (TME) by melatonin.
Mu Q; Najafi M
Eur J Pharmacol; 2021 Sep; 907():174365. PubMed ID: 34302814
[TBL] [Abstract][Full Text] [Related]
33. Multifunctional biomimetic nanoparticles loading baicalin for polarizing tumor-associated macrophages.
Han S; Wang W; Wang S; Wang S; Ju R; Pan Z; Yang T; Zhang G; Wang H; Wang L
Nanoscale; 2019 Nov; 11(42):20206-20220. PubMed ID: 31621735
[TBL] [Abstract][Full Text] [Related]
34. Targeting of the tumor microenvironment by curcumin.
Fu X; He Y; Li M; Huang Z; Najafi M
Biofactors; 2021 Nov; 47(6):914-932. PubMed ID: 34375483
[TBL] [Abstract][Full Text] [Related]
35. Polymeric indoximod based prodrug nanoparticles with doxorubicin entrapment for inducing immunogenic cell death and improving the immunotherapy of breast cancer.
Zang X; Song J; Yi X; Piyu J
J Mater Chem B; 2022 Mar; 10(12):2019-2027. PubMed ID: 35254372
[TBL] [Abstract][Full Text] [Related]
36. Regulatory cells and the effect of cancer immunotherapy.
Iglesias-Escudero M; Arias-González N; Martínez-Cáceres E
Mol Cancer; 2023 Feb; 22(1):26. PubMed ID: 36739406
[TBL] [Abstract][Full Text] [Related]
37. Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy.
Joshi S; Sharabi A
Pharmacol Ther; 2022 Jul; 235():108114. PubMed ID: 35122833
[TBL] [Abstract][Full Text] [Related]
38. Effects of CSF1R-targeted chimeric antigen receptor-modified NK92MI & T cells on tumor-associated macrophages.
Zhang P; Zhao S; Wu C; Li J; Li Z; Wen C; Hu S; An G; Meng H; Zhang X; Yang L
Immunotherapy; 2018 Aug; 10(11):935-949. PubMed ID: 30149762
[TBL] [Abstract][Full Text] [Related]
39. Remodeling tumor immune microenvironment via targeted blockade of PI3K-γ and CSF-1/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy.
Li M; Li M; Yang Y; Liu Y; Xie H; Yu Q; Tian L; Tang X; Ren K; Li J; Zhang Z; He Q
J Control Release; 2020 May; 321():23-35. PubMed ID: 32035193
[TBL] [Abstract][Full Text] [Related]
40. Targeting and repolarizing M2-like tumor-associated macrophage-mediated MR imaging and tumor immunotherapy by biomimetic nanoparticles.
Chong L; Jiang YW; Wang D; Chang P; Xu K; Li J
J Nanobiotechnology; 2023 Oct; 21(1):401. PubMed ID: 37907987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
